BioSpace News Archive

AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies in the country, has updated its list of limited distribution drugs announced Aug. 12.

The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronization therapy.

Today, the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative®— announced a request for proposals (RFP) from organizations working to fight stigma, increase access to health services, and increase local leadership for those living with HIV in the South.

The many voices of patients with IgA nephropathy, a chronic kidney disease, will come together on Monday, August 19, during an Externally-led Patient-focused Drug Development (EL-PFDD) meeting in Hyattsville, MD.

PPG (NYSE:PPG) today announced that the PPG Foundation invested more than $1.5 million in 48 organizations to support educational and community sustainability programs throughout the U.S.

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF)

Online mail-order pharmacy selected for “Healthcare in America” documentary

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).

For the first time in its 38-year history, Chicago-based AbelsonTaylor, one of the world’s premier health and wellness advertising agencies, has a new president

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD), presented three-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago.